WVU Cancer Institute became the first in the world to treat ultra-rare, aggressive CD19-positive MPAL with subcutaneous ...

An ongoing phase 2 trial (NCT07222579) has seen early success with a new subcutaneous formulation of blinatumomab (Blincyto) in a patient with CD19-positive mixed phenotype acute leukemia (MPAL), a ...

The randomized phase III AALL1731 trial presented at the American Society of Hematology annual meeting showed that adding the bispecific T-cell engager blinatumomab (Blincyto) to chemotherapy ...

Please provide your email address to receive an email when new articles are posted on . Adding blinatumomab to consolidation chemotherapy improved 3-year OS and RFS. A higher percentage of patients ...

Please provide your email address to receive an email when new articles are posted on . The addition of blinatumomab to chemotherapy improved DFS for children with B-cell ALL. Researchers stopped ...

Blinatumomab has rapidly emerged as a cornerstone in the treatment of B-cell ALL (B-ALL) across age and risk groups. Initially approved for minimal residual disease (MRD)–positive adult B-ALL in 2018, ...

Many older adults with B-cell precursor acute lymphoblastic leukemia (BCP-ALL) have a relapse despite having a measurable residual disease (MRD)–negative complete remission with combination ...

Neoadjuvant Chemotherapy in High-Grade Myxoid Liposarcoma: Results of the Expanded Cohort of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish Sarcoma Groups (PSG) Data ...

In a final 5-year follow-up analysis of a phase 3 trial, blinatumomab consolidation therapy demonstrated superior event-free survival and overall survival than conventional chemotherapy among children ...

Blinatumomab addition to chemotherapy significantly improves survival and reduces relapse in pediatric B-cell acute lymphoblastic leukemia, especially in high-risk groups. The trial demonstrated that ...